Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator
and plasminogen activator inhibitor type 1.
suPAR: soluble urokinase-type plasminogen activator
receptor; IL-6: interleukin-6; CRP: c-reactive protein; CI: confidence interval.
Yonemura et al., "Association of immunohistochemical detection of urokinase-type plasminogen activator
with metastasis and prognosis in colorectal cancer," Oncology, vol.
Kapoor et al., "A reassessment of soluble urokinase-type plasminogen activator
receptor in glomerular disease," Kidney International, vol.
Matucci Cerinic, "The urokinase-type plasminogen activator
system and inflammatory joint diseases," Clinical and Experimental Rheumatology, vol.
Soluble urokinase-type plasminogen activator
receptor (suPAR) as an independent factor predicting worse prognosis and extra-bone marrow involvement in multiple myeloma patients.
Induction of urokinase-type plasminogen activator
by the anthracycline antibiotic in human RC-K8 lymphoma and H69 lung-carcinoma cells.
ViroGates A/S (Birkerod, Denmark) has patented a method of diagnosing and/or prognosticating HIV infection in a subject comprising the steps of: (a) performing in vitro a measurement of the level of a marker in the form of (i) urokinase plasminogen activator receptor (uPAR), (ii) soluble urokinase plasminogen activator receptor (suPAR), (iii) urokinase-type plasminogen activator
(uPA), (iv) one or more degradation products of (i), (ii) or (iii), and/or (v) an mRNA for (i), (ii) or (iii), in a biological fluid sample from a subject, and (b) using the measurement value obtained to evaluate the state of the subject.
Relation of serum vascular endothelial growth factor as an angiogenesis biomarker with nitric oxide and urokinase-type plasminogen activator
in breast cancer patients.
Specifically, the researchers have examined the effects of alcohol and polyphenols on the expression of proteins and pathways that can lead to increased fibrinolysis (including, tissue-type plasminogen activator, t-PA; urokinase-type plasminogen activator
, u-PA and plasminogen activator inhibitor type 1, PAI-1).
The researchers studied urokinase-type plasminogen activator
(uPA) and its inhibitor, called PAI-1, proteins that are involved in cell migration within the body.
Several biomarkers look promising, but the combination of urokinase-type plasminogen activator
(uPA) and plasma activation inhibitor-1 (PAI-1) is actually ready for prime time use in clinical practice, Dr.